For decades, the idea of a drug that could rewind aspects of human aging has belonged more to science fiction than hospital formularies. That boundary is starting to blur as a gene therapy called ...

In a bid to treat blindness, Life Biosciences will try out potent cellular reprogramming technology on volunteers.

The placebo-controlled, double-blind, randomised Phase I trial involved 100 healthy participants.

Add Yahoo as a preferred source to see more of our stories on Google. Alzheimer's disease, the most common form of dementia, is responsible for tens of millions of cases around the world. Jens Kalaene ...

Neuralink is preparing to begin its first human clinical trials of the Blindsight implant in 2026, which aims to restore vision for people with complete blindness.Neuralink Founder Elon Musk ...

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-human ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS and Parkinson's.

The Phase I trial will recruit participants who have been diagnosed with non-arteritic anterior ischaemic optic neuropathy ...

GALVESTON, Texas--(BUSINESS WIRE)--Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials ...

Memorial Sloan Kettering Cancer Center's mission is to end cancer. To get there, the famed organization must keep improving clinical care and research, including clinical trials. It has as many as ...

On January 9th, GENEIII reaffirmed its global leadership in ergothioneine production and scientific validation at the ...